Drug
Baricitinib 4 MG Oral Tablet
Baricitinib 4 MG Oral Tablet is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_4
2
40%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(2)
Detailed Status
Completed2
Not yet recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
Trials by Status
completed240%
active_not_recruiting120%
not_yet_recruiting240%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingphase_4
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
NCT06240351
not_yet_recruitingphase_3
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
NCT07279688
not_yet_recruitingphase_2
Baricitinib in CPPD - the BAPTIST Study
NCT06768294
completedphase_4
Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
NCT05660655
completedphase_2
Baricitinib Therapy in COVID-19
NCT04358614
Clinical Trials (5)
Showing 5 of 5 trials
NCT06240351Phase 4
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
NCT07279688Phase 3
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
NCT06768294Phase 2
Baricitinib in CPPD - the BAPTIST Study
NCT05660655Phase 4
Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
NCT04358614Phase 2
Baricitinib Therapy in COVID-19
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5